Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.
Identifieur interne : 001065 ( PubMed/Checkpoint ); précédent : 001064; suivant : 001066Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.
Auteurs : Leisha A. Emens [États-Unis] ; Paolo A. Ascierto [Italie] ; Phillip K. Darcy [Australie] ; Sandra Demaria [États-Unis] ; Alexander M M. Eggermont [France] ; William L. Redmond [États-Unis] ; Barbara Seliger [Allemagne] ; Francesco M. Marincola [Qatar]Source :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2017.
Descripteurs français
- KwdFr :
- MESH :
- antagonistes et inhibiteurs : Antigène CTLA-4, Récepteur-1 de mort cellulaire programmée.
- traitement médicamenteux : Tumeurs.
- usage thérapeutique : Antinéoplasiques.
- Association thérapeutique, Humains, Immunothérapie, Thérapie moléculaire ciblée.
English descriptors
- KwdEn :
- MESH :
- chemical , antagonists & inhibitors : CTLA-4 Antigen, Programmed Cell Death 1 Receptor.
- chemical , therapeutic use : Antineoplastic Agents.
- drug therapy : Neoplasms.
- methods : Immunotherapy, Molecular Targeted Therapy.
- Combined Modality Therapy, Humans.
Abstract
Cancer immunotherapy is now established as a powerful way to treat cancer. The recent clinical success of immune checkpoint blockade (antagonists of CTLA-4, PD-1 and PD-L1) highlights both the universal power of treating the immune system across tumour types and the unique features of cancer immunotherapy. Immune-related adverse events, atypical clinical response patterns, durable responses, and clear overall survival benefit distinguish cancer immunotherapy from cytotoxic cancer therapy. Combination immunotherapies that transform non-responders to responders are under rapid development. Current challenges facing the field include incorporating immunotherapy into adjuvant and neoadjuvant cancer therapy, refining dose, schedule and duration of treatment and developing novel surrogate endpoints that accurately capture overall survival benefit early in treatment. As the field rapidly evolves, we must prioritise the development of biomarkers to guide the use of immunotherapies in the most appropriate patients. Immunotherapy is already transforming cancer from a death sentence to a chronic disease for some patients. By making smart, evidence-based decisions in developing next generation immunotherapies, cancer should become an imminently treatable, curable and even preventable disease.
DOI: 10.1016/j.ejca.2017.01.035
PubMed: 28623775
Affiliations:
- Allemagne, Australie, France, Italie, Qatar, États-Unis
- Maryland, Oregon, Victoria (État), État de New York, Île-de-France
- Melbourne
- Université de Melbourne
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28623775Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.</title><author><name sortKey="Emens, Leisha A" sort="Emens, Leisha A" uniqKey="Emens L" first="Leisha A" last="Emens">Leisha A. Emens</name><affiliation wicri:level="2"><nlm:affiliation>Johns Hopkins University School of Medicine, Department of Oncology, Graduate Program in Pathobiology, Baltimore, MD 21287, USA. Electronic address: emensle@jhmi.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Johns Hopkins University School of Medicine, Department of Oncology, Graduate Program in Pathobiology, Baltimore, MD 21287</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Ascierto, Paolo A" sort="Ascierto, Paolo A" uniqKey="Ascierto P" first="Paolo A" last="Ascierto">Paolo A. Ascierto</name><affiliation wicri:level="1"><nlm:affiliation>Istituto Nazionale Tumori Fondazione G. Pascale, Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Napoli, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto Nazionale Tumori Fondazione G. Pascale, Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Napoli</wicri:regionArea><wicri:noRegion>Napoli</wicri:noRegion></affiliation></author><author><name sortKey="Darcy, Phillip K" sort="Darcy, Phillip K" uniqKey="Darcy P" first="Phillip K" last="Darcy">Phillip K. Darcy</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville 3010</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Demaria, Sandra" sort="Demaria, Sandra" uniqKey="Demaria S" first="Sandra" last="Demaria">Sandra Demaria</name><affiliation wicri:level="2"><nlm:affiliation>Weill Cornell Medical College, Department of Radiation Oncology, New York, NY 10065, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Weill Cornell Medical College, Department of Radiation Oncology, New York, NY 10065</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Eggermont, Alexander M M" sort="Eggermont, Alexander M M" uniqKey="Eggermont A" first="Alexander M M" last="Eggermont">Alexander M M. Eggermont</name><affiliation wicri:level="3"><nlm:affiliation>Cancer Institute Gustave-Roussy, 114 Rue Edouard Vaillant, Villejuif/Paris-Sud 94800, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Cancer Institute Gustave-Roussy, 114 Rue Edouard Vaillant, Villejuif/Paris-Sud 94800</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Redmond, William L" sort="Redmond, William L" uniqKey="Redmond W" first="William L" last="Redmond">William L. Redmond</name><affiliation wicri:level="2"><nlm:affiliation>Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213</wicri:regionArea><placeName><region type="state">Oregon</region></placeName></affiliation></author><author><name sortKey="Seliger, Barbara" sort="Seliger, Barbara" uniqKey="Seliger B" first="Barbara" last="Seliger">Barbara Seliger</name><affiliation wicri:level="1"><nlm:affiliation>Martin Luther University, Institute for Medical Immunology, Magdeburger Str. 2, 06112 Halle, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Martin Luther University, Institute for Medical Immunology, Magdeburger Str. 2, 06112 Halle</wicri:regionArea><wicri:noRegion>06112 Halle</wicri:noRegion><wicri:noRegion>06112 Halle</wicri:noRegion><wicri:noRegion>06112 Halle</wicri:noRegion></affiliation></author><author><name sortKey="Marincola, Francesco M" sort="Marincola, Francesco M" uniqKey="Marincola F" first="Francesco M" last="Marincola">Francesco M. Marincola</name><affiliation wicri:level="1"><nlm:affiliation>Research Branch, Sidra Medical and Research Centre, Doha, Qatar. Electronic address: fmarincola@sidra.org.</nlm:affiliation><country xml:lang="fr">Qatar</country><wicri:regionArea>Research Branch, Sidra Medical and Research Centre, Doha</wicri:regionArea><wicri:noRegion>Doha</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28623775</idno><idno type="pmid">28623775</idno><idno type="doi">10.1016/j.ejca.2017.01.035</idno><idno type="wicri:Area/PubMed/Corpus">000827</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000827</idno><idno type="wicri:Area/PubMed/Curation">000824</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000824</idno><idno type="wicri:Area/PubMed/Checkpoint">000824</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000824</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.</title><author><name sortKey="Emens, Leisha A" sort="Emens, Leisha A" uniqKey="Emens L" first="Leisha A" last="Emens">Leisha A. Emens</name><affiliation wicri:level="2"><nlm:affiliation>Johns Hopkins University School of Medicine, Department of Oncology, Graduate Program in Pathobiology, Baltimore, MD 21287, USA. Electronic address: emensle@jhmi.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Johns Hopkins University School of Medicine, Department of Oncology, Graduate Program in Pathobiology, Baltimore, MD 21287</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Ascierto, Paolo A" sort="Ascierto, Paolo A" uniqKey="Ascierto P" first="Paolo A" last="Ascierto">Paolo A. Ascierto</name><affiliation wicri:level="1"><nlm:affiliation>Istituto Nazionale Tumori Fondazione G. Pascale, Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Napoli, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto Nazionale Tumori Fondazione G. Pascale, Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Napoli</wicri:regionArea><wicri:noRegion>Napoli</wicri:noRegion></affiliation></author><author><name sortKey="Darcy, Phillip K" sort="Darcy, Phillip K" uniqKey="Darcy P" first="Phillip K" last="Darcy">Phillip K. Darcy</name><affiliation wicri:level="4"><nlm:affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville 3010</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Demaria, Sandra" sort="Demaria, Sandra" uniqKey="Demaria S" first="Sandra" last="Demaria">Sandra Demaria</name><affiliation wicri:level="2"><nlm:affiliation>Weill Cornell Medical College, Department of Radiation Oncology, New York, NY 10065, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Weill Cornell Medical College, Department of Radiation Oncology, New York, NY 10065</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Eggermont, Alexander M M" sort="Eggermont, Alexander M M" uniqKey="Eggermont A" first="Alexander M M" last="Eggermont">Alexander M M. Eggermont</name><affiliation wicri:level="3"><nlm:affiliation>Cancer Institute Gustave-Roussy, 114 Rue Edouard Vaillant, Villejuif/Paris-Sud 94800, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Cancer Institute Gustave-Roussy, 114 Rue Edouard Vaillant, Villejuif/Paris-Sud 94800</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Redmond, William L" sort="Redmond, William L" uniqKey="Redmond W" first="William L" last="Redmond">William L. Redmond</name><affiliation wicri:level="2"><nlm:affiliation>Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213</wicri:regionArea><placeName><region type="state">Oregon</region></placeName></affiliation></author><author><name sortKey="Seliger, Barbara" sort="Seliger, Barbara" uniqKey="Seliger B" first="Barbara" last="Seliger">Barbara Seliger</name><affiliation wicri:level="1"><nlm:affiliation>Martin Luther University, Institute for Medical Immunology, Magdeburger Str. 2, 06112 Halle, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Martin Luther University, Institute for Medical Immunology, Magdeburger Str. 2, 06112 Halle</wicri:regionArea><wicri:noRegion>06112 Halle</wicri:noRegion><wicri:noRegion>06112 Halle</wicri:noRegion><wicri:noRegion>06112 Halle</wicri:noRegion></affiliation></author><author><name sortKey="Marincola, Francesco M" sort="Marincola, Francesco M" uniqKey="Marincola F" first="Francesco M" last="Marincola">Francesco M. Marincola</name><affiliation wicri:level="1"><nlm:affiliation>Research Branch, Sidra Medical and Research Centre, Doha, Qatar. Electronic address: fmarincola@sidra.org.</nlm:affiliation><country xml:lang="fr">Qatar</country><wicri:regionArea>Research Branch, Sidra Medical and Research Centre, Doha</wicri:regionArea><wicri:noRegion>Doha</wicri:noRegion></affiliation></author></analytic><series><title level="j">European journal of cancer (Oxford, England : 1990)</title><idno type="eISSN">1879-0852</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (therapeutic use)</term><term>CTLA-4 Antigen (antagonists & inhibitors)</term><term>Combined Modality Therapy</term><term>Humans</term><term>Immunotherapy (methods)</term><term>Molecular Targeted Therapy (methods)</term><term>Neoplasms (drug therapy)</term><term>Programmed Cell Death 1 Receptor (antagonists & inhibitors)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antigène CTLA-4 (antagonistes et inhibiteurs)</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Association thérapeutique</term><term>Humains</term><term>Immunothérapie ()</term><term>Récepteur-1 de mort cellulaire programmée (antagonistes et inhibiteurs)</term><term>Thérapie moléculaire ciblée ()</term><term>Tumeurs (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>CTLA-4 Antigen</term><term>Programmed Cell Death 1 Receptor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Antigène CTLA-4</term><term>Récepteur-1 de mort cellulaire programmée</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunotherapy</term><term>Molecular Targeted Therapy</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Combined Modality Therapy</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Association thérapeutique</term><term>Humains</term><term>Immunothérapie</term><term>Thérapie moléculaire ciblée</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cancer immunotherapy is now established as a powerful way to treat cancer. The recent clinical success of immune checkpoint blockade (antagonists of CTLA-4, PD-1 and PD-L1) highlights both the universal power of treating the immune system across tumour types and the unique features of cancer immunotherapy. Immune-related adverse events, atypical clinical response patterns, durable responses, and clear overall survival benefit distinguish cancer immunotherapy from cytotoxic cancer therapy. Combination immunotherapies that transform non-responders to responders are under rapid development. Current challenges facing the field include incorporating immunotherapy into adjuvant and neoadjuvant cancer therapy, refining dose, schedule and duration of treatment and developing novel surrogate endpoints that accurately capture overall survival benefit early in treatment. As the field rapidly evolves, we must prioritise the development of biomarkers to guide the use of immunotherapies in the most appropriate patients. Immunotherapy is already transforming cancer from a death sentence to a chronic disease for some patients. By making smart, evidence-based decisions in developing next generation immunotherapies, cancer should become an imminently treatable, curable and even preventable disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28623775</PMID><DateCreated><Year>2017</Year><Month>06</Month><Day>17</Day></DateCreated><DateCompleted><Year>2017</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0852</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>European journal of cancer (Oxford, England : 1990)</Title><ISOAbbreviation>Eur. J. Cancer</ISOAbbreviation></Journal><ArticleTitle>Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.</ArticleTitle><Pagination><MedlinePgn>116-129</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0959-8049(17)30918-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2017.01.035</ELocationID><Abstract><AbstractText>Cancer immunotherapy is now established as a powerful way to treat cancer. The recent clinical success of immune checkpoint blockade (antagonists of CTLA-4, PD-1 and PD-L1) highlights both the universal power of treating the immune system across tumour types and the unique features of cancer immunotherapy. Immune-related adverse events, atypical clinical response patterns, durable responses, and clear overall survival benefit distinguish cancer immunotherapy from cytotoxic cancer therapy. Combination immunotherapies that transform non-responders to responders are under rapid development. Current challenges facing the field include incorporating immunotherapy into adjuvant and neoadjuvant cancer therapy, refining dose, schedule and duration of treatment and developing novel surrogate endpoints that accurately capture overall survival benefit early in treatment. As the field rapidly evolves, we must prioritise the development of biomarkers to guide the use of immunotherapies in the most appropriate patients. Immunotherapy is already transforming cancer from a death sentence to a chronic disease for some patients. By making smart, evidence-based decisions in developing next generation immunotherapies, cancer should become an imminently treatable, curable and even preventable disease.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Emens</LastName><ForeName>Leisha A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Department of Oncology, Graduate Program in Pathobiology, Baltimore, MD 21287, USA. Electronic address: emensle@jhmi.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ascierto</LastName><ForeName>Paolo A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Istituto Nazionale Tumori Fondazione G. Pascale, Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darcy</LastName><ForeName>Phillip K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demaria</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Weill Cornell Medical College, Department of Radiation Oncology, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eggermont</LastName><ForeName>Alexander M M</ForeName><Initials>AMM</Initials><AffiliationInfo><Affiliation>Cancer Institute Gustave-Roussy, 114 Rue Edouard Vaillant, Villejuif/Paris-Sud 94800, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redmond</LastName><ForeName>William L</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR 97213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seliger</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Martin Luther University, Institute for Medical Immunology, Magdeburger Str. 2, 06112 Halle, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marincola</LastName><ForeName>Francesco M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Research Branch, Sidra Medical and Research Centre, Doha, Qatar. Electronic address: fmarincola@sidra.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Cancer</MedlineTA><NlmUniqueID>9005373</NlmUniqueID><ISSNLinking>0959-8049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060908">CTLA-4 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060908" MajorTopicYN="N">CTLA-4 Antigen</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer immunotherapy</Keyword><Keyword MajorTopicYN="N">Cytotoxic T lymphocyte antigen-4 (CTLA-4)</Keyword><Keyword MajorTopicYN="N">Immune checkpoint blockade</Keyword><Keyword MajorTopicYN="N">Programmed death ligand-1 (PD-L1)</Keyword><Keyword MajorTopicYN="N">Programmed death-1 (PD-1)</Keyword><Keyword MajorTopicYN="N">Tumour immunity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>01</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28623775</ArticleId><ArticleId IdType="pii">S0959-8049(17)30918-8</ArticleId><ArticleId IdType="doi">10.1016/j.ejca.2017.01.035</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>France</li><li>Italie</li><li>Qatar</li><li>États-Unis</li></country><region><li>Maryland</li><li>Oregon</li><li>Victoria (État)</li><li>État de New York</li><li>Île-de-France</li></region><settlement><li>Melbourne</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Emens, Leisha A" sort="Emens, Leisha A" uniqKey="Emens L" first="Leisha A" last="Emens">Leisha A. Emens</name></region><name sortKey="Demaria, Sandra" sort="Demaria, Sandra" uniqKey="Demaria S" first="Sandra" last="Demaria">Sandra Demaria</name><name sortKey="Redmond, William L" sort="Redmond, William L" uniqKey="Redmond W" first="William L" last="Redmond">William L. Redmond</name></country><country name="Italie"><noRegion><name sortKey="Ascierto, Paolo A" sort="Ascierto, Paolo A" uniqKey="Ascierto P" first="Paolo A" last="Ascierto">Paolo A. Ascierto</name></noRegion></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Darcy, Phillip K" sort="Darcy, Phillip K" uniqKey="Darcy P" first="Phillip K" last="Darcy">Phillip K. Darcy</name></region></country><country name="France"><region name="Île-de-France"><name sortKey="Eggermont, Alexander M M" sort="Eggermont, Alexander M M" uniqKey="Eggermont A" first="Alexander M M" last="Eggermont">Alexander M M. Eggermont</name></region></country><country name="Allemagne"><noRegion><name sortKey="Seliger, Barbara" sort="Seliger, Barbara" uniqKey="Seliger B" first="Barbara" last="Seliger">Barbara Seliger</name></noRegion></country><country name="Qatar"><noRegion><name sortKey="Marincola, Francesco M" sort="Marincola, Francesco M" uniqKey="Marincola F" first="Francesco M" last="Marincola">Francesco M. Marincola</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001065 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001065 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:28623775
|texte= Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28623775" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |